Literature DB >> 9231478

Quality-of-life measures in asthma--do they matter to the GP?

K Gruffydd-Jones.   

Abstract

Asthma is a condition which incurs a great cost to the National Health Service, to the economy and above all to the patient in terms of loss of quality of life. Treatments for asthma need to be evaluated for their cost-effectiveness. Traditional outcome measures, such as airflow measurements have their limitations, especially in mild to moderate asthma. Quality-of-life measurements represent the impact of asthma on the everyday lives of asthmatics across the whole disease spectrum. Disease specific quality-of-life questionnaires, such as the Asthma Quality-of-Life Questionnaire (AQLQ), provide reliable instruments in reflecting disease severity, but also in detecting changes in quality of life produced by different asthma treatments. Quality-of-life measures are becoming increasingly important and are end-points of therapeutic asthma trials in primary care, but should be used in conjunction with more surrogate markers of asthma severity such as peak flow.

Entities:  

Mesh:

Year:  1997        PMID: 9231478      PMCID: PMC1313035     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  11 in total

1.  A quality-of-life method for estimating the value of avoided morbidity.

Authors:  M T French; J A Mauskopf
Journal:  Am J Public Health       Date:  1992-11       Impact factor: 9.308

2.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

3.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

4.  Parental perceptions and attitudes toward asthma and its treatment: a controlled study.

Authors:  J E Donnelly; W J Donnelly; Y H Thong
Journal:  Soc Sci Med       Date:  1987       Impact factor: 4.634

5.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics.

Authors:  E F Juniper; P A Kline; M A Vanzieleghem; E H Ramsdale; P M O'Byrne; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1990-10

6.  A quantitative approach to perceived health status: a validation study.

Authors:  S M Hunt; S P McKenna; J McEwen; E M Backett; J Williams; E Papp
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

7.  The Sickness Impact Profile: development and final revision of a health status measure.

Authors:  M Bergner; R A Bobbitt; W B Carter; B S Gilson
Journal:  Med Care       Date:  1981-08       Impact factor: 2.983

8.  Validation of an asthma quality of life diary in a clinical trial.

Authors:  M E Hyland; G R Crocker
Journal:  Thorax       Date:  1995-07       Impact factor: 9.139

9.  Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life.

Authors:  M P Rutten-van Mölken; F Custers; E K van Doorslaer; C C Jansen; L Heurman; F P Maesen; J J Smeets; A M Bommer; J A Raaijmakers
Journal:  Eur Respir J       Date:  1995-06       Impact factor: 16.671

10.  Increased nitric oxide in exhaled air of asthmatic patients.

Authors:  S A Kharitonov; D Yates; R A Robbins; R Logan-Sinclair; E A Shinebourne; P J Barnes
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

View more
  2 in total

1.  Relationship between anxiety, depression, and morbidity in adult asthma patients.

Authors:  L D Rimington; D H Davies; D Lowe; M G Pearson
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations.

Authors:  William M Tierney; J Franklin Roesner; Roopa Seshadri; Michael G Lykens; Michael D Murray; Morris Weinberger
Journal:  J Gen Intern Med       Date:  2004-03       Impact factor: 5.128

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.